CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update. Strengthened Cash, Strategic Refocus and Pipeline Progress De ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Edlow and her team's prior work evaluating prenatal administration of the COVID-19 mRNA vaccines demonstrated that timing of ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Pharmaceutical giant Merck(NYSE: MRK) is recognized for its extensive product ... The global blue chip biopharma company is ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Evidence shows that the vaccines used in Canada are very effective at preventing severe illness, hospitalization and death from COVID-19. It's important to receive a primary series and a booster dose ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...